Thinking on BIOSECURE diligence,
vendor screening, and the policy that shapes it.
Published
Topic
Policy
The clinical timeline is no longer the monopoly concern of the biotech sector.
ReadPublished
Topic
Policy
This Summer, the OMB will release a memo that will provide critical depth to the BIOSECURE Act. This memo is more important than the list of names expected in December.
ReadPublished
Topic
Industry
A $32 million series A compliance company is at the center of a fraud investigation that has the RegTech sector dumbfounded.
ReadPublished
Topic
Policy
Firms focused only on surface-level BIOSECURE compliance may be missing the larger signal about biotech supply chain transparency.
Read